Cargando…
Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity
Innate immunity acts as the first line of defense against pathogen invasion. During Toxoplasma gondii infection, multiple innate immune sensors are activated by invading microbes or pathogen-associated molecular patterns (PAMPs). However, how inflammasome is activated and its regulatory mechanisms d...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765454/ https://www.ncbi.nlm.nih.gov/pubmed/36214572 http://dx.doi.org/10.1128/mbio.02361-22 |
_version_ | 1784853490510594048 |
---|---|
author | Hu, Zhiqiang Wu, Dan Lu, Jiansen Zhang, Yufen Yu, Shao-Meng Xie, Yingchao Li, Hongyu Yang, Jianwu Lai, De-Hua Zeng, Ke Jiang, Huaji Lun, Zhao-Rong Yu, Xiao |
author_facet | Hu, Zhiqiang Wu, Dan Lu, Jiansen Zhang, Yufen Yu, Shao-Meng Xie, Yingchao Li, Hongyu Yang, Jianwu Lai, De-Hua Zeng, Ke Jiang, Huaji Lun, Zhao-Rong Yu, Xiao |
author_sort | Hu, Zhiqiang |
collection | PubMed |
description | Innate immunity acts as the first line of defense against pathogen invasion. During Toxoplasma gondii infection, multiple innate immune sensors are activated by invading microbes or pathogen-associated molecular patterns (PAMPs). However, how inflammasome is activated and its regulatory mechanisms during T. gondii infection remain elusive. Here, we showed that the infection of PRU, a lethal type II T. gondii strain, activates inflammasome at the early stage of infection. PRU tachyzoites, RNA and soluble tachyzoite antigen (STAg) mainly triggered the NLRP3 inflammasome, while PRU genomic DNA (gDNA) specially activated the AIM2 inflammasome. Furthermore, mice deficient in AIM2, NLRP3, or caspase-1/11 were more susceptible to T. gondii PRU infection, and the ablation of inflammasome signaling impaired antitoxoplasmosis immune responses by enhancing type I interferon (IFN-I) production. Blockage of IFN-I receptor fulfilled inflammasome-deficient mice competent immune responses as WT mice. Moreover, we have identified that the suppressor of cytokine signaling 1 (SOCS1) is a key negative regulator induced by inflammasome-activated IL-1β signaling and inhibits IFN-I production by targeting interferon regulatory factor 3 (IRF3). In general, our study defines a novel protective role of inflammasome activation during toxoplasmosis and identifies a critical regulatory mechanism of the cross talk between inflammasome and IFN-I signaling for understanding infectious diseases. |
format | Online Article Text |
id | pubmed-9765454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-97654542022-12-21 Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity Hu, Zhiqiang Wu, Dan Lu, Jiansen Zhang, Yufen Yu, Shao-Meng Xie, Yingchao Li, Hongyu Yang, Jianwu Lai, De-Hua Zeng, Ke Jiang, Huaji Lun, Zhao-Rong Yu, Xiao mBio Research Article Innate immunity acts as the first line of defense against pathogen invasion. During Toxoplasma gondii infection, multiple innate immune sensors are activated by invading microbes or pathogen-associated molecular patterns (PAMPs). However, how inflammasome is activated and its regulatory mechanisms during T. gondii infection remain elusive. Here, we showed that the infection of PRU, a lethal type II T. gondii strain, activates inflammasome at the early stage of infection. PRU tachyzoites, RNA and soluble tachyzoite antigen (STAg) mainly triggered the NLRP3 inflammasome, while PRU genomic DNA (gDNA) specially activated the AIM2 inflammasome. Furthermore, mice deficient in AIM2, NLRP3, or caspase-1/11 were more susceptible to T. gondii PRU infection, and the ablation of inflammasome signaling impaired antitoxoplasmosis immune responses by enhancing type I interferon (IFN-I) production. Blockage of IFN-I receptor fulfilled inflammasome-deficient mice competent immune responses as WT mice. Moreover, we have identified that the suppressor of cytokine signaling 1 (SOCS1) is a key negative regulator induced by inflammasome-activated IL-1β signaling and inhibits IFN-I production by targeting interferon regulatory factor 3 (IRF3). In general, our study defines a novel protective role of inflammasome activation during toxoplasmosis and identifies a critical regulatory mechanism of the cross talk between inflammasome and IFN-I signaling for understanding infectious diseases. American Society for Microbiology 2022-10-10 /pmc/articles/PMC9765454/ /pubmed/36214572 http://dx.doi.org/10.1128/mbio.02361-22 Text en Copyright © 2022 Hu et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Hu, Zhiqiang Wu, Dan Lu, Jiansen Zhang, Yufen Yu, Shao-Meng Xie, Yingchao Li, Hongyu Yang, Jianwu Lai, De-Hua Zeng, Ke Jiang, Huaji Lun, Zhao-Rong Yu, Xiao Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity |
title | Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity |
title_full | Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity |
title_fullStr | Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity |
title_full_unstemmed | Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity |
title_short | Inflammasome Activation Dampens Type I IFN Signaling to Strengthen Anti-Toxoplasma Immunity |
title_sort | inflammasome activation dampens type i ifn signaling to strengthen anti-toxoplasma immunity |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9765454/ https://www.ncbi.nlm.nih.gov/pubmed/36214572 http://dx.doi.org/10.1128/mbio.02361-22 |
work_keys_str_mv | AT huzhiqiang inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT wudan inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT lujiansen inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT zhangyufen inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT yushaomeng inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT xieyingchao inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT lihongyu inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT yangjianwu inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT laidehua inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT zengke inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT jianghuaji inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT lunzhaorong inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity AT yuxiao inflammasomeactivationdampenstypeiifnsignalingtostrengthenantitoxoplasmaimmunity |